Polycystic ovary syndrome.
Conditions
Interventions
Intervention 1: Intervention group: Received oral Berberine at a dose of 300 mg, four times a day for at least 2 months. The drug was purchased from Fazl Darou Pharmaceutical Company under the brand n
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Women aged 18 to 45 Diagnosis of the disease based on the Rotterdam criteria BMI between 18.5 and 35
Exclusion criteria
Exclusion criteria: Taking chemical and herbal medications that affect insulin, sex hormones, or blood lipid levels within the last two months IVF treatment Having diabetes, thyroid disease, hyperprolactinemia, severe liver or kidney disease Pregnancy, breastfeeding, or menopause
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fast blood suger. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;Fast insulin. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;Hemoglobin A1C. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;HOMA-IR index. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: In this study, fasting insulin and fasting glucose levels are collected from blood samples and calculated using the insulin resistance index formula.;Blood cholesterol. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;High-density lipoprotein. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;Low-density lipoprotein. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;Triglyceride. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;Luteinising Hormone. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;Follicle-stimulating hormone. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;Sex hormone-binding globulin. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;Total Testosterone. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;Dehydroepiandrosterone. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;Dihydrotestosterone. Timepoint: Beginning and end of the study (two months after starting use). Method of measurement: Blood test.;Anti-Mullerian hormone. Timep | — |
Secondary
| Measure | Time frame |
|---|---|
| Waist-to-hip ratio. Timepoint: Beginning and end of the study. Method of measurement: Tape measure at standard points (such as the ends of the shoulders and hips).;Weight. Timepoint: Beginning and end of the study. Method of measurement: Calibrated scale.;Body mass index. Timepoint: Beginning and end of the study. Method of measurement: Calculated based on weight and height.;Hirsutism. Timepoint: Beginning and end of the study. Method of measurement: Using the simplified Freeman-Galloway model, in which only a few key areas (e.g., upper lip, lower abdomen, and thighs) are assessed.;Acne. Timepoint: Beginning and end of the study. Method of measurement: It is assessed using the IGA Score by a trained professional and based on a standard classification.;Menstrual characteristics. Timepoint: Beginning and end of the study. Method of measurement: Participants are assessed through a standard questionnaire about the duration of bleeding and the interval between menstrual periods. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoud zarinkolah
Shiraz University of Medical Sciences
Outcome results
None listed